Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate

ADAM10 and ADAM17 have been shown to contribute to the acquired drug resistance of HER2-positive breast cancer in response to trastuzumab. The majority of ADAM10 and ADAM17 inhibitor development has been focused on the discovery of compounds that bind the active site zinc, however, in recent years,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Sci Rep
Main Authors: Madoux, Franck, Dreymuller, Daniela, Pettiloud, Jean-Phillipe, Santos, Radleigh, Becker-Pauly, Christoph, Ludwig, Andreas, Fields, Gregg B., Bannister, Thomas, Spicer, Timothy P., Cudic, Mare, Scampavia, Louis D., Minond, Dmitriy
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5431342/
https://ncbi.nlm.nih.gov/pubmed/28442704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-016-0013-4
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares